Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to shrink advanced cervical tumors

NCT ID NCT04865887

Recruiting now Disease control Sponsor: Georgetown University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs, pembrolizumab and lenvatinib, can shrink tumors in people with advanced cervical cancer that has stopped responding to initial treatment. The trial enrolls 35 adults whose cancer has spread or cannot be removed by surgery. The goal is to see if this combination improves response rates and delays cancer progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER METASTATIC CERVICAL CANCER

Contacts and locations

Locations

  • Georgia Cancer Center at Augusta University

    RECRUITING

    Augusta, Georgia, 30912, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • John Theurer Cancer Center at Hackensack UMC

    RECRUITING

    Hackensack, New Jersey, 07601, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • MedStar Georgetown University Hospital

    RECRUITING

    Washington D.C., District of Columbia, 20007, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Medstar Washington Hospital Center

    WITHDRAWN

    Washington D.C., District of Columbia, 20010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.